MedTrace Logo

LoBAG30 Diet in Patients on Metformin

NCT00607867 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-12-12

Study results available
· View outcomes & findings →

Summary

We will determine the metabolic response to a Low Biologically Available Glucose Diet (LoBAG30) in subjects currently receiving the maximum dose of metformin as monotherapy in whom the glycohemoglobin is not at an acceptable level (\>8.0%). Our hypothesis is that introduction of a LoBAG30 diet to subjects currently treated with a full therapeutic dose of metformin will improve blood glucose control in people who have not achieved an acceptable total glycohemoglobin on metformin alone.

Conditions

Interventions

OTHER

LoBAG30 diet

A LoBAG30 diet consists of 30% of total energy intake as carbohydrate, 30% protein, and 40% fat.

OTHER

Control Diet

A control diet consists of 55% of total energy intake as carbohydrate, 15% protein, 30% fat

Sponsors & Collaborators

Principal Investigators

  • Mary Gannon, PhD · Minneapolis Veterans Affairs Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2011-01-31
Completion
2011-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00607867 on ClinicalTrials.gov